A scientific leader with an excellent track record in leading both protein therapeutics and small molecule projects from target research to early clinical studies.
Wenyan Miao comes to ROME after leading drug discovery for autoimmune diseases and immuno-oncology at Celsius Therapeutics as vice president of immunology and inflammation. Prior to that, she served as executive director of immunology at Nimbus Therapeutics. Wenyan also played a major role on the team that led the IND filing and successful Phase I trial of the Nimbus ACC program, which was acquired by Gilead Sciences in 2016 for a total deal value of $1.2 billion. Wenyan has considerable expertise across R&D, from target discovery to early clinical proof-of-mechanism studies. Among her previous positions: posts at Repligen, Pfizer, Wyeth, AbbVie and Millennium Pharmaceuticals. Wenyan has a B.S. in biochemistry from Fudan University in Shanghai and a Ph.D. in biochemistry and molecular biology from Indiana University School of Medicine.